The efficacy and tolerability of a fixed combination of 160 mg sabal fruit extract WS 1473 and 120 mg urtica root extract WS 1031 per capsule (PRO 160/120) was investigated in elderly, male patients suffering from lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia in a prospective multicenter trial. A total of 257 patients (129 and 128, respectively) were randomized to treatment with PRO 160/120 or placebo (127 and 126 were evaluable for efficacy). Following a single-blind placebo run-in phase of 2 weeks, the patients received 2 x 1 capsule/day of the study medication under double-blind conditions over a period of 24 weeks. Double-blind treatment was followed by an open control period of 24 weeks during which all patients were administered PRO 160/120. Outcome measures for treatment efficacy included the assessment of the patients' LUTS by means of the I-PSS self-rating questionnaire and a quality of life index as well as uroflow and sonographic parameters. Using the International Prostate Symptom Score (I-PSS), patients treated with PRO 160/120 exhibited a substantially higher total score reduction after 24 weeks of double-blind treatment than patients of the placebo group (6 points vs 4 points; P=0.003, one tailed) with a tendency in the same direction after 16 weeks. This applied to obstructive as well as to irritative symptoms, and to patients with moderate or severe symptoms at baseline. Patients randomized to placebo showed a marked improvement in LUTS (as measured by the I-PSS) after being switched to PRO 160/120 during the control period (P=0.01, one tailed, in comparison to those who had been treated with PRO 160/120 in the double-blind phase). The tolerability of PRO 160/120 was comparable to the placebo. In conclusion, PRO 160/120 was clearly superior to the placebo for the amelioration of LUTS as measured by the I-PSS. PRO 160/120 is advantageous in obstructive and irritative urinary symptoms and in patients with moderate and severe symptoms. The tolerability of the herbal extract was excellent.

In an open-label extension of a randomized, double-blind clinical trial, the long-term efficacy and tolerability of a fixed combination of 160 mg Sabal fruit extract WS 1473 and 120 mg Urtica root extract WS 1031 per capsule (PRO 160/120) were investigated in elderly men with moderate or severe lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). Two hundred and fifty-seven patients were randomly treated with 2 x 1 capsule/day PRO 160/120 or placebo for 24 weeks, followed by a 24-week control period and a 48-week follow-up period in which all patients received PRO 160/120. Efficacy measures included the assessment of LUTS [International Prostate Symptom Score ((I-PSS) self-rating questionnaire] and uroflow and sonographic parameters. Two hundred and nineteen subjects participated in the follow-up. Between baseline and end of observation (week 96) the I-PSS total score was reduced by 53% (P < 0.001), peak and average urinary flow increased by 19% (P < 0.001), and residual urine volume decreased by 44% (P = 0.03). The incidence of adverse events during follow-up was one in 1,181 treatment days; in only one event a causal relationship with intake of PRO 160/120 could not be excluded. Treatment with PRO 160/120 thus provides a clinically relevant benefit over a period of 96 weeks.

Исследовано 236 пациентов с диагнозом рак легких I-III стадии за период 2010-2017 гг. В работе описаны ближайшие результаты радикального хирургического лечения (пневмонэктомия, лоб-и билобэктомия) у больных раком легких I-III стадии. В зависимости от способа хирургического лечения пациенты были разделены на 3 группы. В первой группе больных (n=63) применялась только пневмонэктомия, закрытие культи бронха сшивающим аппаратом (УО-40). Во второй группе больных (n=143) выполняли лоб-или билобэктомию, закрытие культи бронха сшивающим аппаратом (УО-40). В третьей группе больных (n=30) выполняли лоб-или билобэктомию, закрытие культи бронха сшивающим аппаратом (УО-40) и отдельными П-образными узловыми швами (викрил 3-0) от 4 до 6 узлов. Всем больным после торакотомии выполняли дренирование плевральной полости двумя дренажами у куполу плевральной полости и в синус. Во всех трех группах послеоперационное лечение выполнялось по стандарту. Между группами не было выявлено значимых различий по полу, возрасту, характеру сопутствующей патологии. Радикальное оперативное лечение показано пациентам с резектабельным раком независимо от возраста, при этом самым эффективным хирургическим способом является лоб-или билобэктомия с закрытием культи бронха сшивающим аппаратом и отдельными П-образными узловыми швами. Ключевые слова: рак легких, пневмонэктомия, лоб-и билобэктомия. Depending on the method of surgical treatment the patients were divided into 3 groups. In the first group of patients was used only pneumonectomy, closure of the bronchial stump stapling apparatus. In the second group, patients fulfilled the forehead-or bilobectomy, closure of the bronchial stump stapling apparatus. In the third group of patients carried out the forehead-or bilobectomy, closure of the bronchial stump suturing unit and a separate U-shaped node joints. Between groups there was no significant differences in sex, age, nature of comorbidity. Radical surgical treatment is indicated in patients with resectable cancer, regardless of age and the most effective surgical method is the forehead-or bilobectomy with closure of the bronchial stump suturing unit and a separate U-shaped node joints. Keywords: lung cancer, pneumonectomy, lob-and bilobectomy. EVALUATION OF SURGICAL TREATMENT OF PATIENTS WITH LUNG CANCERДанные статистики показывают, что рак легкого является одним из самых распространенных онкологических заболеваний, и частота его продолжает расти [1][2][3].Хирургическое лечение этой патологии продолжает оставаться основным, оно включает резекционные методы, такие как пневмонэктомия, лоб-или билобэктомия [4][5][6].Радикальное хирургическое лечение имеет негативные стороны: высокая травматичность, трофические и репаративные расстройства, гнойно-воспалительные осложнения достигают 30 % и дают летальность до 9 % [7][8][9]. Бронхиальные свищи -самые грозные осложнения радикального лечения рака легкого [7,10,11]. Во многих хирургических клиниках мира, специализирующихся на лечении больных раком легкого, данное осложнение после пневмонэктомий достигает 12 %...

No abstract

SUMMARY Uterine arteries embolization (UAE) is one of the modern trends in the treatment of uterine bleeding caused by uterine leiomyomas (UL). However, unfavourable results of this method of treatment are observed in 10–15% of cases. This is primarily concerned with the emerging ischemia of ovarian tissue after embolization.Material and methods Complex examination and treatment was performed in 48 patients admitted with UL complicated by the development of uterine bleeding. Patients with UL were divided into two groups. In the Group I of patients (n=29) standard embolization was performed, while the patients of the Group II (n=19) with diagnosed interarterial utero-ovarian anastomosis underwent separating technique of UA occlusion using different types of emboli.Results and discussion The features of the uterine blood supply in patients with UL were analyzed from the perspective of the effecacy and safety of endovascular intervention. A methodology of staged EUA was developed, which involved the staged aortography of the infrarenal aorta (for visualization of the ovarian arteries); pelvic arteriography (for evaluating the vascular anatomy of the pelvis and identifying utero-ovarian intearterial anastomoses); selective arteriography followed by UAE first with cylindrical emboli, and then with standard emboli in the form of microspheres. The application of the developed technique did not show dysfunction of the ovaries in both the short and long-term follow-up period up to 18 months in the Group II.Conclusion The separating UA occlusion is a safe and effective way of preventing ischemic damage in the presence of signoficant utero-ovarian inter-arterial nastomoses.